This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck & Co.’s cancer immunotherapy Keytruda is one of ...
The use of immunotherapy in patients with various types of cancer has led to dramatic increases in survival. Increased median ...
Ivonescimab’s progression-free survival data in non-small cell lung cancer bode well for an upcoming overall survival readout ...
Ivonescimab combined with chemotherapy for locally advanced or metastatic NSCLC resistant to EGFR-TKI therapy, which has now been approved for marketing in China and added to China’s National ...
The biological functions of VEGF-B in cancer progression remain poorly understood. Here, we report that VEGF-B promotes cancer metastasis through the remodeling of tumor microvasculature. Knockdown of ...
The literature presented in this review does not indicate a clinically relevant relationship between genetic variations in the VEGF system and the risk of CRC. Hence, these markers will probably not ...
Some on Wall Street weren’t too impressed with results from a pivotal trial that tested an Exelixis drug, zanzalintinib, in ...
Compared with the more questionable evidence presented in the risk of CRC and functionality sections of this review, the possible prognostic value of SNPs in the VEGF-A gene in CRC appears more ...
Ivonescimab combined with chemotherapy for locally advanced or metastatic NSCLC resistant to EGFR-TKI therapy, which has now been approved for marketing in China and added to China's National ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback